SCHEMBL3765155

SCHEMBL3765155

[c]1ncccc1N1CCOc2ccccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NUDT1 P36639 1/20 0.46
NOTUM Q6P988 1/20 0.40
PDK1 Q15118 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
PIK3CA P42336 2/20 0.38
PIK3CD O00329 2/20 0.38
PIK3CB P42338 2/20 0.38
PIK3CG P48736 2/20 0.38
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37
PIK3R1 P27986 1/20 0.37
MTOR P42345 1/20 0.37
MAPT P10636 1/20 0.36
NPC1 O15118 1/20 0.36
POLB P06746 2/20 0.35
KMT2A Q03164 1/20 0.35
P2RY1 P47900 1/20 0.34
LMNA P02545 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3764747 0.76 NOTUM (0.43) NUDT1NOTUMPDK1MKNK1MKNK2
SCHEMBL2789857 0.73 NUDT1 (0.55) NUDT1NOTUMPDK1MKNK1MKNK2
SCHEMBL3422889 0.72 ROCK1 (0.49) NUDT1NOTUMMAPTPOLBKMT2A
SCHEMBL28346864 0.71 NOTUM (0.49) NUDT1NOTUMPDK1MKNK1MKNK2
SCHEMBL2495797 0.70 NUDT1 (0.48) NUDT1NOTUMPDK1MKNK1MKNK2
SCHEMBL19337215 0.69 MKNK1 (0.56) NUDT1NOTUMPDK1MKNK1MKNK2
SCHEMBL22465938 0.67 NOTUM (0.45) NUDT1NOTUMPDK1MKNK1MKNK2
SCHEMBL10094229 0.67 NUDT1 (0.45) NUDT1NOTUMPDK1MKNK1MKNK2
SCHEMBL2789106 0.67 PIK3CA (0.46) NUDT1NOTUMPDK1MKNK1MKNK2
SCHEMBL441105 0.66 LMNA (0.42) PIK3CAMAPTNPC1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2029570-B1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA SA (BE) 2014-10-15 EP disclosed
US-8324204-B2 Fused thiophene derivatives as kinase inhibitors UCB PHARMA SA (BE) 2012-12-04 US disclosed
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-12-02 US disclosed
WO-2009122148-A1 FUSED THIOPHENE AND THIAZOLE DERIVATIVES AS PI3K KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-10-08 WO disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
WO-2009071890-A1 TRICYCLIC KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 WO disclosed
EP-2029570-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB Pharma S.A. (BE) 2009-03-04 EP disclosed
WO-2007141504-A1 FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2007-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305066-A1 Fused Thiophene Derivatives as Kinase Inhibitors PIKFYVE, PI4KA, PIK3CA NUDT1 2721/4885NOTUM 1802/4885PDK1 173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.